

Int J Gen Med. 2012; 5: 449–454.

Published online 2012 May 21. doi: [10.2147/IJGM.S31433](https://doi.org/10.2147/IJGM.S31433)

PMCID: PMC3367409

PMID: [22675263](https://pubmed.ncbi.nlm.nih.gov/22675263/)

New approach to beta cell function screening by nitric oxide assessment of obese individuals at the population level

[Elinton Adami Chaim](#) and [Renata Cristina Gobato](#)

University of Campinas (UNICAMP), Faculty of Medical Sciences, Department of Surgery, Cidade Universitária Zeferino Vaz, Barão Geraldo, Brazil

Correspondence: Elinton Adami Chaim, University of Campinas (UNICAMP), Faculty of Medical Sciences, Department of Surgery, Cidade Universitária Zeferino Vaz, Barão Geraldo, PO Box 6111, 13083970 Campinas, SP Brazil, Tel +193 788 9447, Email chaim@hc.unicamp.br

Copyright © 2012 Chaim and Gobato, publisher and licensee Dove Medical Press Ltd

This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

Abstract

Go to: Go to:

Background

Go to: Go to:

Approximately 27% of Americans today are obese, and this condition increases the prevalence of metabolic syndrome and diabetes. The UK Prospective Diabetes Study suggests that loss of beta cell function can begin at least 10 years before diagnosis, and mean beta cell function is already less than 50% at diagnosis. The aim of this research was to assess the possibility of detecting loss of beta cell function in obese patients by a novel approach involving nitric oxide assessment using a combination of technologies.

Materials and methods

Go to: Go to:

One hundred and fifteen obese patients (93 women, 22 men) of mean age 39 (range 17–62) years, who were candidates for bariatric surgery were included in the study, and underwent laboratory tests, including fasting blood glucose, fasting insulin plasma, and examination with the Electro Sensor complex. The Electro Sensor complex offers a new way to assess nitric oxide production using five technologies managed by software, ie, the galvanic skin response, photoelectrical plethysmography, heart rate variability analysis, bioimpedance analysis, and blood pressure oscillometric measurements. The homeostasis model assessment 2% beta cell function (HOMA2% β) algorithm was calculated from fasting blood glucose and fasting insulin plasma using free software provided by The University of Oxford Diabetes Trial Unit. The Electro Sensor complex percent beta (ESC% β) algorithm was calculated from the Electro Sensor complex data and statistical neural network. Statistical analysis was performed to correlate ESC% β and HOMA2% β using the coefficient of correlation and Spearman's coefficient of rank correlation. Receiver-operating characteristic curves were also constructed to determine the specificity and sensitivity of ESC% β in detecting a HOMA2% β value < 100.

Results

Go to: Go to:

The coefficient of correlation between ESC% β and HOMA2% β was 0.72 (using log values) and the

Spearman's coefficient of rank correlation (ρ) was 0.799 ($P < 0.0001$). ESC% β had a sensitivity of 77.14% and specificity of 78.21% (cutoff ≤ 157 , corresponding to 40% after conversion into a 0%–100% scale) to detect a HOMA2% β value < 100 ($P < 0.0001$).

Conclusion

Go to: Go to:

The ESC% β algorithm has a high predictive correlation with HOMA2% β , and good specificity and sensitivity to detect a HOMA2% β value < 100 . Therefore, the Electro Sensor complex enabling nitric oxide assessment represents a novel method of screening for beta cell function in the obese population on a large scale. Such a tool, which is easy to administer, noninvasive, and cost-effective, would be of great benefit for widespread screening of beta cell function in obese patients.

Keywords: beta cell function, Electro Sensor complex, nitric oxide assessment, ESC% β algorithm, HOMA2% β algorithm, obese population, screening

Introduction

Go to: Go to:

During the past 20 years, the US has succumbed to a pervasive obesity epidemic.^{1,2} In 1980, less than 47% of Americans were overweight (body mass index > 25 kg/m²) and less than 15% were obese (body mass index > 30 kg/m²). Today, approximately 67% of Americans are overweight and over 27% are obese.^{2,3} Obesity increases the prevalence of the metabolic syndrome and diabetes.^{4,5} The pathogenesis of type 2 diabetes is hypothesized to be related to two principal factors, ie, insulin resistance and impaired glucose tolerance cell function.⁶ How do insulin resistance and beta cell dysfunction combine to cause type 2 diabetes?⁷ Over time, changes in insulin resistance and secretion lead to the onset of type 2 diabetes. In the early stages, as insulin resistance rises, there is a compensatory increase in insulin secretion and glucose levels remain normal (normoglycemia). However, in the long term, as beta cell function begins to fail, insulin secretion decreases, impaired glucose tolerance and hyperglycemia become apparent, and frank type 2 diabetes develops.

Impaired glucose tolerance may be defined as higher than normal blood glucose levels, but not high enough to be called diabetes. People with impaired glucose tolerance may or may not go on to develop diabetes. Glucose levels before (fasting) and after (post-prandial) meals increase steadily as the individual progresses from normoglycemia to impaired glucose tolerance and, finally, to type 2 diabetes.

Extrapolation of the observed rate of decline in beta cell function in diet-treated subjects in the UK Prospective Diabetes Study suggests that loss of beta cell function can start at least 10 years before diagnosis of diabetes, and that mean beta cell function may already be less than 50% at diagnosis.^{8,9} None of the therapies used in the UK Prospective Diabetes Study (sulfonylureas, metformin, and insulin) were able to prevent or delay the progressive deterioration of beta cell function.¹⁰ On average, beta cell function declines by 1% per year with normal aging, compared with 4% per year in diabetes.^{10,11} In view of these facts and the studies that have already established the correlation between obesity and insulin resistance, we undertook this study of screening for beta cell function in the obese population.

Beta cell function diagnostics are already available. The gold standard test includes the hyperinsulinemic-euglycemic clamp,¹¹ and another accepted method is the minimal-model analysis frequently sampled intravenous glucose tolerance test.¹² The oral glucose tolerance test is also accepted as a noninvasive minimal model for analysis.¹² However, these tests are invasive, labor-

intensive, and/or expensive, which discourages their use in large population-based epidemiologic studies. Sometimes used as a marker for beta cell dysfunction, the ratio of proinsulin (the precursor of insulin that is converted to insulin) to total insulin provides a measure of the efficiency of proinsulin processing.¹³ C-peptide is also used to assess beta cell function in type 1 diabetes when the insulin level is not interpretable due to insulin medication.¹⁴

The homeostasis model assessment percent beta (HOMA% β) algorithm is appropriate for large-scale screening,¹⁵ and the new HOMA2% β algorithm improves the ability to assess beta cell function compared with the HOMA1% β algorithm.¹⁶ The HOMA2% β is an algorithm calculated from fasting blood glucose and plasma insulin, and correlates well with estimates using the euglycemic clamp method. It has been tested extensively against minimal-model analysis, and has been accepted for large-scale screening of beta cell function,¹⁷ with some restrictions, ie, in older patients.¹⁸

The Electro Sensor complex (LD Technology, Miami, FL) is a combination of five technologies managed by software, and the accuracy of some features, such as fat mass and cardiac output measurements, has been compared with recognized standardized assessment.¹⁹ The Electro Sensor complex features include the galvanic skin response, heart rate variability analysis, photoelectrical plethysmography analysis, and blood pressure measurements. We consider that the Electro Sensor complex data are related to production of nitric oxide.

Electro Sensor complex data and nitric oxide

With regard to the galvanic skin response, electrical skin stimulation seems to be a mechanical shear stress which causes a phosphorylation cascade that removes phosphate groups from proteins and kinases, activating endothelial nitric oxide synthase to synthesize nitric oxide. Nitric oxide is produced, facilitating the release of cyclic guanosine monophosphate and a change in potassium permeability. Relaxation of smooth muscle and vasodilatation of vessels allows an exchange between the vessels and sweat glands, which facilitates the production of sweat.^{20,21}

Photoelectrical plethysmography analysis provides a stiffness index, and blood pressure measurements are related to endothelial cell function which is related to nitric oxide production.²² Fat mass is also related to nitric oxide.²³ Finally, a study by Sartori et al found a significant relationship between nitric oxide production and heart rate variability analysis.²⁴ Zeng and Quon have performed a study showing the relationship between insulin production and nitric oxide using administration of wortmannin.²⁵ The ESC% β algorithm can be calculated from Electro Sensor complex data. The aim of this research was to assess the possibility of detecting loss of beta cell function in obese patients using a novel approach of nitric oxide assessment using a combination of technologies comparing ESC% β and HOMA2% β .

Materials and methods

Go to: Go to:

Subjects

Obesity is associated with the metabolic syndrome and diabetes, and this study included obese patients who were candidates for bariatric surgery. Patients were excluded if they were on insulin or secretagogue treatment, had a neurological disorder precluding the ability to sign a consent form, were clinically unsuitable candidates for the trial in the opinion of the investigators, and/or had any contraindications to use of the Electro Sensor complex system. Use of the Electro Sensor complex system is contraindicated in the presence of an external defibrillator, skin lesions likely to come into

contact with the electrodes, excessive perspiration, a cardiac pacemaker, electronic life support, any implanted electronic device, inability to remain still for three minutes, metallic pins or prostheses in digits or joints, and absence of a limb.

One hundred and fifteen obese patients (93 women, 22 men) of mean age 39 (range 17–62) years were sent to the laboratory for fasting blood glucose and fasting insulin plasma tests. The patients underwent an Electro Sensor complex measurement before these laboratory tests. The study was approved by the regional ethics committee, and adhered to the ethical principles of the Declaration of Helsinki. Each patient signed an informed consent form, and confidentiality was observed for all participants.

Laboratory tests

Fasting plasma glucose levels (mg/dL) were measured using the colorimetric enzymatic method. Fasting plasma insulin levels ($\mu\text{UI/mL}$) were determined using the chemoluminescent immunoassay. Fasting for 8 hours was required for both tests. The HOMA2% β algorithm was calculated from fasting blood glucose and fasting insulin plasma. Glucose and insulin concentrations were converted to mmol/L and pmol/L, respectively. Calculations were performed using the free software provided by The University of Oxford Diabetes Trial Unit (<http://www.dtu.ox.ac.uk/homacalculator>). Because HOMA is a steady-state model, only clinical realistic values seen in a fasting subject were accepted for analysis (plasma glucose level 3.5–25 mmol/L and plasma insulin level 20–350 pmol/L).

Electro Sensor complex system and ESC% β algorithm

The Electro Sensor complex system is a novel method for assessing nitric oxide production using five technologies managed by software, ie, the galvanic skin response, photoelectrical plethysmography, heart rate variability analysis, bioimpedance analysis, and blood pressure oscillometric measurements.

Nitric oxide assessment is expressed in the ESC% β algorithm, and calculated from the following data:

- Conductance of the foot-foot pathway, expressed in μSi (microSiemens), with a normal range of 8.33–14.71 μSi , from galvanic skin response technology
- Stiffness index, calculated from the height of the patient (in meters) divided by the time (seconds) between the two systolic peaks of the wave provided by the oximeter (photoelectrical plethysmography), expressed in m/sec, with a normal range of 7–9
- Standard deviation normal-to-normal represents the standard deviation of the entire recording of time between each heartbeat, expressed in msec, normal range 40–80, from heart rate variability domain analysis technology
- Fat mass percentage, expressed in kg, with a normal range according to age and gender, from bioimpedance analysis technology
- Systolic pressure, normal range < 140 mmHg, from the blood pressure device using oscillometric technology.

The ESC% β algorithm was performed using statistical neural network analysis software Statistica Version 7.26 Like the HOMA2% β algorithm, the ESC% β algorithm uses a calculator which is integrated into the Electro Sensor complex software, and the results are expressed in percentage form. The scale of results is 0–100, and the normal range is 40%–60%.

Statistical analysis

Statistical analysis of the number of patients needed for the study was calculated using MedCalc software and was 100 on the basis of $\alpha = 5\%$, at 80% power = F (Δ , N, variability DS), taking into account the judgment criteria Δ at approximately 100 DS (5% error). $P < 0.005$ was accepted as being statistically significant. The statistical analysis was performed to correlate the Electro Sensor complex data and HOMA2% β on the one hand, and to correlate ESC% β and HOMA2% β on the other, using the coefficient of correlation and the Spearman's coefficient of rank correlation. Receiver-operating characteristic curves were also constructed to determine the specificity and sensitivity of ESC% β to detect a HOMA2% β value < 100 .

Results

Go to: Go to:

Demographic data for the 115 patients included in the study are summarized in [Table 1](#). The correlation between HOMA2% β and each parameter are summarized in [Table 2](#). Correlation between the ESC% β and the HOMA2% β algorithms is summarized in [Table 3](#). The coefficient of correlation for ESC% β and HOMA2% β is $r = 0.72$ using log values ($P < 0.0001$). Spearman's rank coefficient correlation between ESC% β and HOMA2% β is summarized in [Table 4](#) and in [Figure 1](#). Spearman's rank coefficient correlation (ρ) was 0.799 ($P < 0.0001$). A receiver-operating characteristic curve was constructed to determine the specificity and sensitivity of ESC% β to detect a HOMA2% β value < 100 ([Figure 2](#) and [Table 5](#)). ESC% β had a sensitivity of 77.14% and specificity of 78.21% (cutoff ≤ 157 corresponding to 40% after conversion using a scale of 0%–100%) to detect a HOMA2% β value < 100 ($P < 0.0001$).

[Open in a separate window](#)

[Figure 1](#)

Scatter diagram and regression line ESC% β and HOMA2% β .

Abbreviations: HOMA2% β , homeostasis model assessment 2 percent beta cell function; ESC% β , Electro Sensor complex percent beta.

[Open in a separate window](#)

[Figure 2](#)

Receiver operating characteristic curve ESC% β versus HOMA2% β value < 100 .

Abbreviations: HOMA2% β , homeostasis model assessment 2 percent beta cell function; ESC% β , Electro Sensor complex percent beta.

[Table 1](#)

Demographic data for study participants

[Open in a separate window](#)

Note: Data are expressed as the mean \pm standard deviation.

Abbreviations: BMI, body mass index; SI, stress index; SDNN, standard deviation normal-to-normal; HOMA2% β , homeostasis model assessment 2 percent beta cell function; ESC% β , Electro Sensor complex percent beta.

Table 2

Correlation between HOMA2% β and each parameter

[Open in a separate window](#)

Abbreviations: SI, stiffness index; SDNN, standard deviation normal-to-normal; r, coefficient of correlation; rho, Spearman's coefficient of rank correlation; HOMA2% β , homeostasis model assessment 2 percent beta cell function.

Table 3

Correlation between ESC% β algorithm and HOMA2% β algorithm

[Open in a separate window](#)

Abbreviations: HOMA2% β , homeostasis model assessment 2 percent beta cell function; ESC% β , Electro Sensor complex percent beta.

Table 4

Spearman's coefficient of rank coefficient between ESC% β and HOMA2% β

[Open in a separate window](#)

Abbreviations: HOMA2% β , homeostasis model assessment 2 percent beta cell function; ESC% β , Electro Sensor complex percent beta.

Table 5

Receiver operating characteristic curve analysis: ESC% β versus HOMA2% β value < 100

[Open in a separate window](#)

Notes:

^aDeLong et al 1988 (http://www.medcalc.org/manual/comparison_of_roc_curves.php);

^bbinomial exact (http://www.medcalc.org/manual/comparison_of_roc_curves.php).

Abbreviations: HOMA2% β , homeostasis model assessment 2 percent beta cell function; ESC% β , Electro Sensor complex percent beta.

Discussion

Go to: Go to:

Mayaudon et al²⁷ performed a study using a device which measured foot conductance to detect diabetes. In their study, foot conductance was reduced in diabetic patients compared with control subjects. However, this study compared a group of 92 type 2 diabetic patients of mean age 58.9 ± 12.1 years, body mass index 28.3 ± 5.0 , and mean diabetes duration 14 ± 10 years, with about 50% having diabetic complications and on antidiabetic agents, including insulin and secretagogues, and a group of 41 healthy volunteers of mean age 25.5 ± 6.4 years, none of whom were on treatment, and body mass index 23.8 ± 2.7 . Therefore, the results are biased in that the study compared two very different populations and it would be impossible to attribute the differences in foot conductance to age, complications, treatment, body mass index, or diabetes detection. Also, an algorithm including foot conductance, age, and body mass index was used, which has a sensitivity of 75% and specificity of 100% to detect diabetes. With regard to the differences in age and body mass index between the two study groups, this algorithm result cannot be considered seriously. Ramachandran et al²⁸ have also investigated the same device, the same parameters, and the same algorithm in a study from India using an equivalent population, and the specificity for detecting diabetes was more realistic and failed at 54%. Another study²⁹ using only foot conductance showed this parameter to be useful for evaluating diabetic complications, such as foot neuropathy, but as a sole marker does not have enough specificity and sensitivity to detect diabetes.

Salomaa et al³⁰ performed a cross-sectional study to assess the relationship between arterial stiffness, glucose tolerance, and serum insulin levels. All indices of arterial stiffness were higher when fasting glucose was above the normal level.³¹ Our study confirms this finding, and we found an acceptable correlation comparing HOMA2% β and stiffness index. Schroeder et al³¹ used heart rate variability analysis and the standard deviation normal-to-normal parameter to detect diabetes, and found a good correlation at $P < 0.01$. Our study confirms this finding. Ferrannini et al³² found that fat mass was highly correlated with insulin resistance, but the relationship between fat mass and beta cell function was not clear. Our study included only obese patients with body mass index $> 40 \text{ kg/m}^2$, and this parameter has a low correlation with HOMA2% β .

Finally, Davies et al³³ compared systolic blood pressure and diabetes screening, and found the same correlation that we obtained in the present study. The ESC% β algorithm has a high predictive

correlation with HOMA2% β , and good specificity and sensitivity to detect a HOMA2% β value < 100 . The Electro Sensor complex which provides the ESC% β algorithm could be a new method of estimating beta cell function via nitric oxide assessment using a combination of technologies.

Electro Sensor complex-insulin resistance and Electro Sensor complex-blood glucose control algorithms using different Electro Sensor complex data and formulae have already been investigated and compared, respectively, with HOMA2-IR and glycosylated hemoglobin, with some success (Chaim EA, Gobato RC, Carvalho Ramos M, unpublished data, 2011). Furthermore, the Electro Sensor complex will be useful for early detection of diabetic complications, with regard to the role of nitric oxide in cardiovascular disease³⁴ and renal oxygenation.³⁵ New algorithms using Electro Sensor complex data will be investigated to detect cardiovascular risk and kidney risk. Finally, a longitudinal study is underway at the University of Miami using the Electro Sensor complex to detect diabetes not only in obese patients but also in the general population.

Conclusion

Go to: Go to:

The ESC% β algorithm has a high predictive correlation with the HOMA2% β , and good specificity and sensitivity to detect a HOMA2% β value < 100 , so the Electro Sensor complex system providing nitric oxide assessment would be a new method of screening for beta cell function in the obese population on a large scale. A tool which is easy to administer, noninvasive, and cost-effective would be of advantage and of great benefit for beta cell function screening.

Footnotes

Go to: Go to:

Disclosure

This study was not sponsored and the authors report no conflicts of interest in this work.

References

Go to: Go to:

1. Lewis JE, Schneiderman N. Nutrition, physical activity, weight management, and health. Rev Colomb Psiquiatr. 2006;35:157S. Spanish.
2. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288:1723–1727. [[PubMed](#)]
3. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195–2001. [[PubMed](#)]
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359. [[PubMed](#)]
5. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care. 2005;28:2745–2749. [[PubMed](#)]
6. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Department of Noncommunicable Disease Surveillance; Geneva, Switzerland: World Health Organization: 1999. [Accessed April 19, 2012]. Available from: whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf.
7. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the

pathophysiology of type 2 diabetes. *Diabetologia*. 2003;46(1):3–19. [[PubMed](#)]

8. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. *Diabetes Res Clin Pract*. 1998;40(Suppl):S21–S25. [[PubMed](#)]

9. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16) *Diabetes*. 1995;44:1249–1258. [[PubMed](#)]

10. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) *Lancet*. 1998;352:837–853. [[PubMed](#)]

11. Chiu KC, Lee NP, Cohan P, Chuang L-M. B-cell function declines with age in glucose tolerant Caucasians. *Clin Endocrinol*. 2000;53:569–575. [[PubMed](#)]

12. American Diabetes Association. Screening for type 2 diabetes. *Diabetes Care*. 2003;26:S21–S24. [[PubMed](#)]

13. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. *Eur J Clin Invest*. 2002;32(Suppl 3):35–45. [[PubMed](#)]

14. Picardi A, Visalli N, Lauria A, et al. Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes. *Horm Metab Res*. 2006;38:668–672. [[PubMed](#)]

15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Home-ostasis model assessment: insulin resistance and β -cell function from fasting glucose and insulin concentrations in man. *Diabetologia*. 1985;28:412–419. [[PubMed](#)]

16. Caumo A, Perseghin G, Lattuada G, Ragona F, Livio Luzi AB. Comparing the original (HOMA1) and the updated (HOMA2) method: evidence that HOMA2 is more reliable than HOMA. Abstract 1595-P presented at the 67th Scientific Sessions of the American Diabetes Association; June 22–26, 2007; Chicago, IL.

17. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care*. 2004;27:1487–1495. [[PubMed](#)]

18. Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB, Supiano MA. Limitation of the homeostasis model assessment to predict insulin resistance and β -cell dysfunction in older people. *J Clin Endocrinol Metab*. 2006;91:629–634. [[PubMed](#)]

19. Lewis JE, Tannenbaum SL, Gao J, et al. Comparing the accuracy of ES-BC, EIS and ES Oxi results versus the recognized standardized assessments. *Medical Devices: Evidence and Research*. 2011;4:169–177. [[PMC free article](#)] [[PubMed](#)]

20. Soucy KG, Ryoo S, Benjo A, et al. Impaired shear stress-induced nitric oxide production through decreased NOS phosphorylation contributes to age-related vascular stiffness. *J Appl Physiol*. 2006;101:1751–1759. [[PubMed](#)]

21. Petrofsky J, Hinds CM, Batt J, Prowse M, Suh HJ. The interrelationships between electrical stimulation, the environment surrounding the vascular endothelial cells of the skin, and the role of nitric oxide in mediating the blood flow response to electrical stimulation. *Med Sci Monit*. 2007;13:CR1–7. [[PubMed](#)]

22. Vallance P, Chan N. Endothelial function and nitric oxide: clinical relevance. *Heart*. 2001;85:342–350. [[PMC free article](#)] [[PubMed](#)]
23. Williams L, Wheatcroft B, Shah AM, Kearney MT. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. *Int J Obes*. 2002;26:754–764. [[PubMed](#)]
24. Sartori C, Lepori M, Scherrer U. Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. *Pharmacol Ther*. 2005;106:209–220. [[PubMed](#)]
25. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. *J Clin Invest*. 1996;98:894–898. [[PMC free article](#)] [[PubMed](#)]
26. StatSoft Electronic Statistics Textbook. Statistica automated neural networks. [Accessed April 19, 2012]. Available from: <http://www.statsoft.com/textbook/neural-networks/>
27. Mayaudon H, Miloche PO, Bauduceau B. A new simple method for assessing sudomotor function: relevance in type 2 diabetes. *Diabetes Metab*. 2010;36(Suppl 3):S106–111. [[PubMed](#)]
28. Ramachandran A, Moses A, Shetty S, et al. A new non-invasive technology to screen for dysglycaemia including diabetes. *Diabetes Res Clin Pract*. 2010;88:302–306. [[PubMed](#)]
29. Nazhel B, Yetkin I, Irkeç C, Koçer B. Sympathetic skin response in diabetic neuropathy. *Electromyogr Clin Neurophysiol*. 2002;42:181–185. [[PubMed](#)]
30. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. *Circulation*. 1995;91:1432–1443. [[PubMed](#)]
31. Schroeder EB, Chambless LE, Liao D, et al. Diabetes, glucose, insulin, and heart rate variability. *Diabetes Care*. 2005;28:668–674. [[PubMed](#)]
32. Ferrannini E, Camastra S, Gastaldelli A, et al. Beta-cell function in obesity: effects of weight loss. *Diabetes*. 2004;53(Suppl 3):S26–S33. [[PubMed](#)]
33. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. *Diabet Med*. 2000;17:433–440. [[PubMed](#)]
34. Naseem KM. The role of nitric oxide in cardiovascular diseases. *Mol Aspects Med*. 2005;26:33–65. [[PubMed](#)]
35. Palm F, Teerlink T, Hansell P. Nitric oxide and kidney oxygenation. *Curr Opin Nephrol Hypertens*. 2009;18:68–73. [[PubMed](#)]